Because of the potential for increased medication toxicity and costs related to treatment of colorectal cancer (CRC), identifying individuals most likely to respond to targeted therapies is essential for appropriate patient management. We offer comprehensive next-generation sequencing to identify genetic variations associated with therapeutic outcomes. We also offer microsatellite instability (MSI) testing and mismatch repair (MMR) analysis to assess how likely patients are to benefit from certain treatment options.
NEXT-GENERATION SEQUENCING TEST MENU
While monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can block the growth and spread of colorectal cancer, studies have shown that tumors with specific gene mutations will not respond to these therapies. Based on internal Mayo Clinic data, Mayo Clinic Laboratories’ expanded genetic panel identified 24% more patients who are unlikely to benefit from EGFR-targeted therapy. Our next-generation sequencing panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.
Anti-PD-L1 immunotherapies such as pembrolizumab have recently emerged as a therapeutic option in CRC. These therapies are designed to block the PD-L1/PD-1 immune checkpoint pathway, thereby assisting the immune system in tumor cell detection. However, current data indicates that only patients with defective MMR and/or high MSI are likely to benefit from this therapy. Our rapid tumor microsatellite instability (TMSI) evaluation is the only clinically available assay of its kind to offer fast test results.
Fill out the form below and one of our specialists will be in touch.